To determine whether the loss of the C-terminal tail impacts the previously reported anticancer activity of HMGB1-fl, the activities of the full-length and truncated forms of HMGB1 were evaluated on the HeLa cervix carcinoma cell line and a panel of colorectal cancer (CRC) cells with different genetic and phenotypic profiles (Table S1). This evidence concerns the gene HMGB1 and colorectal carcinoma.